Insider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 2,960 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) insider Tamer I. Khayal sold 2,960 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $133.10, for a total transaction of $393,976.00. Following the completion of the sale, the insider now owns 20,843 shares of the company’s stock, valued at $2,774,203.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

TransMedics Group Stock Up 0.5 %

Shares of TMDX stock traded up $0.61 during trading hours on Wednesday, reaching $135.09. The company had a trading volume of 782,644 shares, compared to its average volume of 769,708. The company has a market capitalization of $4.45 billion, a P/E ratio of -402.94 and a beta of 1.95. The company has a debt-to-equity ratio of 3.18, a quick ratio of 8.76 and a current ratio of 9.72. TransMedics Group, Inc. has a twelve month low of $36.42 and a twelve month high of $144.23. The stock’s fifty day simple moving average is $110.02 and its 200 day simple moving average is $90.69.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The company had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. During the same quarter last year, the company earned ($0.08) earnings per share. TransMedics Group’s revenue for the quarter was up 132.9% on a year-over-year basis. As a group, sell-side analysts expect that TransMedics Group, Inc. will post 0.76 earnings per share for the current fiscal year.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in TMDX. Venturi Wealth Management LLC acquired a new stake in shares of TransMedics Group during the first quarter valued at about $30,000. Fidelis Capital Partners LLC purchased a new stake in TransMedics Group during the 1st quarter worth approximately $35,000. Cutler Group LLC CA increased its holdings in TransMedics Group by 600.0% during the 3rd quarter. Cutler Group LLC CA now owns 700 shares of the company’s stock worth $38,000 after purchasing an additional 600 shares during the last quarter. First Horizon Advisors Inc. raised its position in shares of TransMedics Group by 26.8% in the 4th quarter. First Horizon Advisors Inc. now owns 1,049 shares of the company’s stock valued at $83,000 after purchasing an additional 222 shares in the last quarter. Finally, RiverPark Advisors LLC boosted its stake in shares of TransMedics Group by 19.5% during the 4th quarter. RiverPark Advisors LLC now owns 1,319 shares of the company’s stock valued at $104,000 after buying an additional 215 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on TMDX. Morgan Stanley boosted their price objective on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. lifted their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Stephens assumed coverage on TransMedics Group in a research note on Tuesday. They set an “overweight” rating and a $151.00 price target for the company. Oppenheimer lifted their price objective on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday, May 1st. Finally, Canaccord Genuity Group boosted their target price on TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $123.57.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.